Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2006

View Archived Issues

Intranasal insulin demonstrates therapeutic benefits in AD

Facial rejuvenation product ICX-RHY completes phase I

Novartis steps up activities for flu cell culture vaccines

UMMS signs license and research agreements with CytoDyn for flu vaccines

German approval for new phosphate binding agent OsvaRen

Orphan drug designations for YSPSL in U.S. and Europe

Wyeth and ArQule present new gamma secretase inhibitors with Notch-sparing selectivity

Ovation launches NeoProfen for premature infants with patent ductus arteriosus

Nanobodies targeting amyloid-beta peptide

Studies detail metabolic effects, efficacy of aripiprazole in schizophrenia

Japanese researchers present novel Abeta aggregation inhibitor

Pfizer begins Exubera introduction with education and training program

aP2 implicated in allergic airway inflammation: possible link between metabolic and immune disorders

Ostarine phase II proof-of-concept study completes enrollment

Aridol filed for approval in Switzerland

Phase III begins for Actos + TAK-536 combination product

Novel BiTE molecule presented

Lilly and Alcon sign marketing collaboration for Arxxant

NDA submission for SPD-465 for ADHD

Foamix's betamethasone foam shows efficacy and good usability in psoriasis

New compounds for respiratory disorders reported in recent patent literature

Patents claim agents with potential for treatment of inflammatory disorders

Radiotherapy using a peptidic vector shows promise in malignant glioma treatment

Sanvar filed for esophageal variceal bleeding in France

In vitro and in vivo pharmacology of novel GluK5 receptor antagonist

Opana and Opana ER now available

Elaprase approved for Hunter's syndrome

New approvable letter for Thelin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...